Premium
Sotrovimab Lowers the Risk of COVID ‐19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates
Author(s) -
Saheb SharifAskari Fatemeh,
Ali Hussain Alsayed Hawra,
Tleyjeh Imad,
Saheb SharifAskari Narjes,
Al Sayed Hussain Ali,
Saddik Basema,
Hamid Qutayba,
Halwani Rabih
Publication year - 2022
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.2700
Subject(s) - favipiravir , medicine , odds ratio , hazard ratio , confidence interval , retrospective cohort study , population , covid-19 , disease , environmental health , infectious disease (medical specialty)
Sotrovimab, an anti‐severe acute respiratory syndrome‐coronavirus 2 monoclonal antibody is being utilized to prevent progression of coronavirus disease 2019 (COVID‐19). Therefore, to understand its benefits, we have conducted a retrospective analysis of all non‐hospitalized patients with symptomatic COVID‐19 who received a single infusion of sotrovimab and/or oral favipiravir at any Dubai COVID‐19 related healthcare center between July 1, 2021, and October 31, 2021. The main outcome was to evaluate the risk of hospitalization for patients with COVID‐19 or all‐cause death within 28 days of treatment initiation. In this analysis, which included 10,882 patients (1,135 in the sotrovimab group, 2,653 in the sotrovimab/favipiravir group, and 7,094 in the favipiravir group), sotrovimab or sotrovimab/favipiravir reduced the risk of hospitalization (13 patients (1.5%) in the sotrovimab group and 71 patients (2.9%) in the sotrovimab/favipiravir group vs. 251 patients (4%) in the favipiravir group; hazard ratio (HR) for sotrovimab: 0.16, 95% confidence interval (CI): 0.09–0.28, P < 0.001; and for sotrovimab/favipiravir, HR: 0.42, 95% CI: 0.32–0.56, P < 0.001), or death by day 28 from the start of treatment (no death in the sotrovimab group and 2 deaths in the the sotrovimab/favipiravir group vs. 10 deaths in the favipiravir group; odds ratio: 0.18, 95% CI: 0.04 to 0.81, P = 026). Safety was assessed in all the 3,788 patients in the sotrovimab and sotrovimab/favipiravir groups, and the reported adverse events were by 34 patients (<1%). In conclusion, sotrovimab was found to reduce the risk of progression of COVID‐19 when administrated early to non‐hospitalized patients with symptomatic COVID‐19. No safety concern was detected.